E

Exact Sciences Corp
D

EXAS

49.250
USD
-0.27
(-0.55%)
مغلق
حجم التداول
119,722
الربح لكل سهم
0
العائد الربحي
-
P/E
-9
حجم السوق
9,148,453,746
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ALGN
    -7.520
    (-3.80%)
    190.370 USD
    ILMN
    ILMN
    -3.080
    (-3.17%)
    94.180 USD
    ISRG
    ISRG
    -15.37
    (-2.53%)
    591.50 USD
    N
    NVCR
    0.420
    (1.94%)
    22.090 USD
    P
    PODD
    -5.82
    (-2.02%)
    282.56 USD
    R
    RGEN
    -3.710
    (-2.28%)
    158.950 USD
    T
    TDOC
    -1.190
    (-9.38%)
    11.490 USD
    T
    TECH
    -0.510
    (-0.78%)
    64.920 USD
    V
    VEEV
    -2.960
    (-1.29%)
    225.900 USD
    المزيد
الأخبار
المقالات

العنوان: Exact Sciences Corp

القطاع: Healthcare
الصناعة: Diagnostics & Research
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, aliquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.